Görüntüleme
7
GİRİŞ: Polisitemia vera (PV) miyeloproliferatif neoplaziler arasında yer alan, başta eritroid seri olmak üzere değişken oranda kan hücrelerinin kontrolsüz çoğalması ve total kan volümünün mutlak artışı ile karakterize, kronik, klonal bir hastalıktır. Prognoz, klinik seyir sırasında ortaya çıkan komplikasyonların ciddiyetine bağlıdır. PV’de, morbidite ve mortalitenin ana nedenini, aynı zamanda tedavi seçeneğini de belirleyen trombotik komplikasyonlar oluşturur. Bu çalışma Mersin bölgesinde polistemia veralı hastalarda, çevresel ve genetik tromboembolik komplikasyon riskini belirlemeye yönelik olarak planlanmıştır. MATERYAL VE METOD: Mersin Üniversitesi Tıp Fakültesi Hastanesinde 2009 ve 2017 yılları arasında dünya sağlık örgütünün belirlemiş olduğu 2001-2008 kriterlerine uygun olarak belirlen polisitemia vera tanısı almış olan 102 hastanın medikal kayıtları incelendi. Hastaların demografik ve klinik verileri, geçirilmiş trombotik olaylar, tanı anındaki laboratuar verileri, retrospektif olarak değerlendirildi. JAK2V617F mutyasonu geleneksel metodlara göre tarandı. BULGULAR: Araştırma popülasyonu 102 PV tanılı hastadan oluşmaktadır, 49’i trombotik olay öyküsü olmayan, 53’u ise trombotik olay öyküsü olan gruptan oluşmakta idi. Trombotik olay öyküsü olan hastalarda yaş yüksek saptandı. Trombotik olay öyküsü olan hastalarda olmayanlara kıyasla HT, kalp hastalığı varlığı, sigara kullanımı ve JAK-2 V617F mutasyon varlığı arasında istatistiksel olarak anlamlı bir ilişki saptandı (p<0,05). SONUÇ: Polistemia veralı hastalarda tromboembolik komplikasyonların JAK2V617F mutasyonu ile ilişkisi bilinmektedir. Arteryal veya venöz trombotik olay bazında bakıldığında sigara kullanımı, HT, JAK-2 V617F pozitifliği trombotik olay gelişme riskini arttıran faktörler olarak ön plana çıkmaktadır.
Polycytemia vera (PV) is a chronic, clonal disease characterized by uncontrollable reproduction of blood cells in variable proportions, primarily erythroid series and absolute increase in total blood volume. The prognosis depends on the severity of complications occurring during the clinical tour. In PV, thrombotic complications that determine the main cause of morbidity and mortality, as well as the treatment option. This study is planned to determine the risk of environmental and genetic tromboembolic complications in patients with polystemia in the Mersin region. The medical records of 102 patients diagnosed with polycythemia vera in accordance with the 2001-2008 criteria determined by the World Health Organization between 2009 and 2017 were examined at the University of Mersin Medical School Hospital. The demographic and clinical data of patients, the trombotic events passed, the laboratory data at the moment of diagnosis, were evaluated as retrospective. JAK2V617F mutation was scanned according to traditional methods. The research population consisted of 102 patients diagnosed with PV, 49 of them had no history of trombotic events and 53 of them had a history of trombotic events. Patients with a history of trombotic occurrence have been diagnosed with an elevated age. In comparison with those in patients with a non-thrombotic event history, a statistically meaningful relationship was found between the presence of HT, heart disease, smoking and the presence of mutation of JAK-2 V617F (p<0,05). The result is known that tromboembolic complications are associated with JAK2V617F mutation in patients with polystemia. When seen on the basis of arterial or venous trombotic events, smoking, HT, JAK-2 V617F positive appears in the forefront as factors that increase the risk of developing trombotic events.
Introduction: With this study, determination of the frequency of thromboembolic complications and the other risk factors that create a predisposition to thromboembolic complications in patients with polycythemia vera (PV) in the Mersin population is aimed. Method: Medical records of 102 patients who were diagnosed with PV between 2009 and 2017 at Univercity of Mersin, Faculty of Medicine in accordance with the 2001-2008 criteria determined by World Health Organization were reviewed. Patients’ demographical data, clinical data, history of previous thrombotic events, treatments they received, and laboratory data at the time of diagnosis were evaluated retrospectively. Results: The study population consisted of 102 patients with PV, 49 patients with no history of thrombotic events and 53 patients with a history of thrombotic events. Mean age was higher in patients with a history of thrombotic event. A statistically significant relationship was found between the presence of HT, presence of heart disease, and the presence of JAK-2 V617F mutation compared to the patients who had a history of thrombotic event. Conclusion: The association of thromboembolic complications with JAK2V617F mutation in patients with polistemia vera is known. Smoking, HT, and JAK-2 V617F positivity are the factors that increase the risk of developing thrombotic events.
Alan : Sağlık Bilimleri
Dergi Türü : Ulusal
Makale Detay 
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Alıntı Yap
Bu Sayfayı Yazdırın
Paylaş
Mendeley
